On 17 January 2018, orphan designation (EU/3/17/1962) was granted by the European Commission to MWB Consulting Ltd, United Kingdom, for humanised Fc-engineered monoclonal antibody against CD19 (also known as XmAb5871) for the treatment of IgG4-related disease.
The sponsorship was transferred to MWB Consulting S.A.R.L., France, in November 2018.
Humanised Fc-engineered monoclonal antibody against CD19
|Disease / condition||
Treatment of IgG4-related disease
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;